New clinical practice guidelines for cannabis and cannabinoid-based medicines (CBMs) have been published due to recent data showing CBMs have a “moderate benefit” in the management of chronic pain.
The researchers performed a literature review and included peer-reviewed articles published between 2001 and 2019 (Cannabis Cannabinoid Res 2023 Mar 27. https://doi.org/10.1089/can.2021.0156). There were 47 studies relevant to pain management, including 22 randomized controlled trials.